WO2010077671A3 - Émulsion de perfluorocarbone stable pour une utilisation en tant que support d'oxygène artificiel - Google Patents

Émulsion de perfluorocarbone stable pour une utilisation en tant que support d'oxygène artificiel Download PDF

Info

Publication number
WO2010077671A3
WO2010077671A3 PCT/US2009/067179 US2009067179W WO2010077671A3 WO 2010077671 A3 WO2010077671 A3 WO 2010077671A3 US 2009067179 W US2009067179 W US 2009067179W WO 2010077671 A3 WO2010077671 A3 WO 2010077671A3
Authority
WO
WIPO (PCT)
Prior art keywords
perfluorocarbon
perfluorocarbon emulsions
artificial oxygen
oxygen carrier
emulsions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/067179
Other languages
English (en)
Other versions
WO2010077671A2 (fr
Inventor
Natalya Y. Rapoport
Glenn D. Prestwich
Russell Morris Condie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Priority to US13/133,126 priority Critical patent/US8673984B2/en
Priority to EP09836718.8A priority patent/EP2373289A4/fr
Publication of WO2010077671A2 publication Critical patent/WO2010077671A2/fr
Publication of WO2010077671A3 publication Critical patent/WO2010077671A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur des émulsions de perfluorocarbone présentant une stabilité élevée et une bonne libération d'oxygène. Ces émulsions de perfluorocarbone sont typiquement destinées à être utilisées en tant que support d'oxygène artificiel. Les émulsions de perfluorocarbone comprennent une phase dispersée composée d'un perfluorocarbone et d'un stabilisateur d'émulsion, et une phase continue. Le stabilisateur d'émulsion peut principalement comprendre un copolymère séquencé de poly(oxyde d'éthylène). Ces émulsions de perfluorocarbone stabilisées peuvent être utilisées dans des phases liquides et/ou d'hydrogel de bioréacteurs de perfusion ou divers autres systèmes de culture pour améliorer la viabilité cellulaire dans des constructions de tissu épais, ou en tant que substituts sanguins, bien que d'autres applications puissent également être envisagées.
PCT/US2009/067179 2008-12-08 2009-12-08 Émulsion de perfluorocarbone stable pour une utilisation en tant que support d'oxygène artificiel Ceased WO2010077671A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/133,126 US8673984B2 (en) 2008-12-08 2009-12-08 Stable perfluorocarbon emulsion for use as an artificial oxygen carrier
EP09836718.8A EP2373289A4 (fr) 2008-12-08 2009-12-08 Émulsion de perfluorocarbone stable pour une utilisation en tant que support d'oxygène artificiel

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20126108P 2008-12-08 2008-12-08
US61/201,261 2008-12-08

Publications (2)

Publication Number Publication Date
WO2010077671A2 WO2010077671A2 (fr) 2010-07-08
WO2010077671A3 true WO2010077671A3 (fr) 2010-08-19

Family

ID=42310495

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/067179 Ceased WO2010077671A2 (fr) 2008-12-08 2009-12-08 Émulsion de perfluorocarbone stable pour une utilisation en tant que support d'oxygène artificiel

Country Status (3)

Country Link
US (1) US8673984B2 (fr)
EP (1) EP2373289A4 (fr)
WO (1) WO2010077671A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404752B2 (en) 2008-07-18 2013-03-26 Oxygen Biotherapeutics, Inc. Method of treating traumatic brain injury
EP2547201A1 (fr) * 2010-03-19 2013-01-23 Oxygen Biotherapeutics, Inc. Crèmes oculaires aux hydrocarbures perfluorés
EP2680819B1 (fr) * 2011-03-04 2019-09-04 The Board of Trustees of The University of Arkansas Émulsion de dodécafluoropentane utilisée comme thérapie pour un accident cérébral vasculaire et une ischémie
WO2013006173A1 (fr) * 2011-07-07 2013-01-10 Empire Technology Development Llc Co-polymères à blocs fluorés
WO2013151537A1 (fr) 2012-04-03 2013-10-10 Empire Technology Development Llc Polymères adhésifs biocompatibles
US20130330389A1 (en) * 2012-06-08 2013-12-12 The Regents Of The University Of Michigan Ultrasound-triggerable agents for tissue engineering
DE102012014464A1 (de) 2012-07-18 2014-01-23 Gmbu E.V., Fachsektion Dresden Formulierung zur topischen Anwendung von Perfluorocarbonverbindungen und Verfahren zur Herstellung
DE102012014465A1 (de) 2012-07-18 2014-01-23 Gmbu E.V., Fachsektion Dresden Perfluorocarbonemulsion
US9670447B2 (en) 2013-01-29 2017-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microfabricated polymeric vessel mimetics
WO2017035454A1 (fr) * 2015-08-26 2017-03-02 University Of Cincinnati Piégeage de l'oxygène dissous via une vaporisation acoustique de gouttelettes
CN111411070A (zh) * 2020-05-15 2020-07-14 河南医学高等专科学校 一种培养基的基层物质、其制备方法、培养基及其应用
CN115517984A (zh) * 2021-06-24 2022-12-27 株式会社爱茉莉太平洋 氧气缓释型纳米乳液组合物以及其制备方法
US20230158144A1 (en) * 2021-11-24 2023-05-25 University Of Utah Research Foundation Ultrasound-triggered nanocarriers
EP4382091A1 (fr) 2022-12-09 2024-06-12 Commissariat à l'Energie Atomique et aux Energies Alternatives Micelles perfluorées et leur utilisations medicales
AU2024412664A1 (en) * 2023-12-27 2026-07-02 Imdpharm Inc. Oxygen carrier pharmaceutical composition containing perfluorocarbon and casein, and preparation method therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4395393A (en) * 1981-08-10 1983-07-26 Basf Wyandotte Corporation Artificial blood emulsifiers
US5904933A (en) * 1994-06-09 1999-05-18 Alliance Pharmaceutical Corp. Stable reverse and multiple fluorocarbon emulsions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2674619A (en) * 1953-10-19 1954-04-06 Wyandotte Chemicals Corp Polyoxyalkylene compounds
IT1050731B (it) * 1974-12-09 1981-03-20 Childrens Hosp Medical Center Composti perfluoropoliciclici per l impiego come sangue sintetico e ambiente di ferfusione
US4443480A (en) 1982-04-12 1984-04-17 Children's Hospital Medical Center Artificial blood and other gas transport agents
JPS60255718A (ja) 1984-05-31 1985-12-17 Green Cross Corp:The パ−フルオロカ−ボン乳剤
JPH0639381B2 (ja) 1985-04-09 1994-05-25 株式会社ミドリ十字 パ−フルオロカ−ボン乳剤
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US5243044A (en) 1986-08-25 1993-09-07 International Therapeutics, Inc. Compounds of perfluoro[3,3,3]propellene and perfluoro hexamethylenetetramine
US5628930A (en) 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
US5595687A (en) 1992-10-30 1997-01-21 Thomas Jefferson University Emulsion stability
AU2000279747A1 (en) * 2000-07-20 2002-02-05 Otkrytoe Aktsionernoe Obschestvo Nauchno-Proizvodstvennaya Firma "Perftoran" Emulsion of perfluororganic compounds for medical purposes, method for producingsaid emulsion and methods for curing and preventing diseases with the aid of the emulsion
AU2005209169B2 (en) * 2004-01-16 2010-12-16 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
US20070026024A1 (en) 2005-07-27 2007-02-01 Drees Thomas C Compositions and methods for emulsifying a pefluorocarbon with an oxygen-carrying surfactant
WO2009134435A2 (fr) * 2008-05-02 2009-11-05 Celsense Inc. Compositions et procédés de production d'émulsions utilisables dans le cadre de techniques de résonance magnétique nucléaire, ainsi que pour d'autres applications

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105798A (en) * 1976-07-19 1978-08-08 Sun Ventures, Inc. Perfluoro polycyclic compounds for use as synthetic blood and perfusion media
US4395393A (en) * 1981-08-10 1983-07-26 Basf Wyandotte Corporation Artificial blood emulsifiers
US5904933A (en) * 1994-06-09 1999-05-18 Alliance Pharmaceutical Corp. Stable reverse and multiple fluorocarbon emulsions

Also Published As

Publication number Publication date
US20110306581A1 (en) 2011-12-15
EP2373289A4 (fr) 2014-07-02
US8673984B2 (en) 2014-03-18
EP2373289A2 (fr) 2011-10-12
WO2010077671A2 (fr) 2010-07-08

Similar Documents

Publication Publication Date Title
Shi et al. A drug‐free, hair follicle cycling regulatable, separable, antibacterial microneedle patch for hair regeneration therapy
Sah et al. Soluble eggshell membrane: a natural protein to improve the properties of biomaterials used for tissue engineering applications
Montalbano et al. Synthesis of bioinspired collagen/alginate/fibrin based hydrogels for soft tissue engineering
Grover et al. Myocardial matrix–polyethylene glycol hybrid hydrogels for tissue engineering
BR112012028786A2 (pt) biorreator para cultura de células e portador para um biorreator
Wu et al. Breadmaking‐Inspired Antioxidant Porous Yeast Microcarriers for Stem Cell Delivery in Diabetic Wound Treatment
WO2011150133A3 (fr) Protéines d'échafaudage à base de fibronectine ayant une stabilité améliorée
WO2008118392A3 (fr) Plate-formes synthétiques de cellules et leurs procédés d'utilisation
WO2011150055A3 (fr) Procédés, substrats, et systèmes utiles pour l'ensemencement cellulaire de greffes médicales
WO2012064429A3 (fr) Peptides entrant dans les cellules et traversant la peau (space) et leurs procédés d'utilisation
WO2011104381A3 (fr) Compositions stables contenant des anticorps
WO2006060182A3 (fr) Peptides hk hautement ramifies utilises en tant que porteurs efficaces de petits arn interferents
WO2008103042A8 (fr) Gélatines de recombinaison enrichies en xrgd présentant une stabilité élevée
WO2009002456A3 (fr) Procédés et compositions associés à des cellules souches
WO2009090558A3 (fr) Compositions pharmaceutiques pouvant mousser de poloxamère avec des agents actifs et/ou des cellules thérapeutiques, et utilisations
WO2014040026A3 (fr) Membrane amniotique et son utilisation dans des produits de construction de cicatrisation des plaies et d'ingénierie tissulaire
Lau et al. Formation of model hepatocellular aggregates in a hydrogel scaffold using degradable genipin crosslinked gelatin microspheres as cell carriers
BR112015019044A2 (pt) adesivos antimicrobianos tendo proprieda-des aperfeiçoadas
IL273159B1 (en) A culture medium preparation, and a method for culturing cells or tissues by using the preparation
WO2012094574A3 (fr) Nanoparticules de polyribonucléotide stabilisées
EP2540764A3 (fr) Composition de poly(organophosphazène) pour biomatériaux
WO2010053297A3 (fr) Membrane électrolytique polymère
WO2011116922A9 (fr) Substrat thermoréactif comportant des microgels, procédé de fabrication de ce substrat et procédé de culture de cellules biologiques
WO2005010160A3 (fr) Cristaux liquides a toxicite reduite et applications associees
MX378896B (es) Control de niveles de dioxido de carbono y ph en reactores de pequeños volumenes,

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09836718

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009836718

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13133126

Country of ref document: US